User:Mr. Ibrahem/Pazopanib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Pazopanib
Clinical data
Pronunciation/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade namesVotrient
AHFS/Drugs.comMonograph
MedlinePlusa610013
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth (tablets)
Drug classTyrosine kinase inhibitor[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability21% (14–39%)[2]
Protein binding>99.5%[2][3]
MetabolismLiver: CYP3A4 (major), 1A2 and 2C8 (minor)[3]
Elimination half-life30.9±4 hours[2]
ExcretionFaeces (primary), urine (<4%)[3]
Identifiers
  • 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide
Chemical and physical data
FormulaC21H23N7O2S
Molar mass437.52 g·mol−1
3D model (JSmol)
  • O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C
  • InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H checkY
  • Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pazopanib, sold under the brand name Votrient, is a medication used to treat renal cell carcinoma (RCC) and certain soft tissue sarcoma.[4] In RCC it is used when other treatments have failed.[4] It is taken by mouth.[4]

Common side effects include diarrhea, high blood pressure, white hair, nausea, tiredness, abdominal pain, low blood cells, and liver problems.[1] Other side effects may include low thyroid, QT prolongation, bleeding, blood clots, and gastrointestinal perforation.[1] Use during pregnancy may harm the baby.[1] It is a tyrosine kinase inhibitor.[1]

Pazopanib was approved for medical use in the United States in 2009.[1] In Europe it received conditional approval in 2010 and full approval in 2013.[5] In the United Kingdom it costs the NHS about £2,250 per month as of 2021.[4] In the United States this amount costs about 14,200 USD.[6]

References[edit]

  1. ^ a b c d e f g "PAZOPanib Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 26 October 2021.
  2. ^ a b c "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived (PDF) from the original on 9 October 2016. Retrieved 8 October 2016.
  3. ^ a b c "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 2 February 2014. Retrieved 27 January 2014.
  4. ^ a b c d e f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1039. ISBN 978-0857114105.
  5. ^ "Votrient". Archived from the original on 22 October 2021. Retrieved 26 October 2021.
  6. ^ "Pazopanib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 26 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Pazopanib&oldid=1194681356"